| Species |
Human |
| Protein Construction |
CD44 (Gln21-Pro220 & Gln386-Ala427)
Accession # P16070-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD44, His, Human at 1μg/ml (100μl/well) on the plate can bind AntiCD44 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
27.91 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-68 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression. |
| Synonyms |
CD44; CDw44; Epican; ECMR-III; LHR; MDU2; MDU3; MIC4; PGP-I; CSPG8; HCELL; HUTCH-I; IN; MC56 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
